ArticleGenes & genomics2026
IRF2 exacerbates diabetic neuropathic pain by promoting high glucose-induced M1 polarization through IL-6/STAT3.
Article in Genes & genomics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundM1 macrophage polarization is a key mechanism in diabetic neuropathic pain (DNP), and interferon regulatory factor 2 (IRF2) has been shown to regulate macrophage polarization.
objectiveThe present study investigated whether IRF2 participates in DNP progression by regulating macrophage polarization.
methodsA DNP mouse model was established using a high-fat diet combined with streptozotocin (STZ), and an in vitro model of RAW264.7 macrophages stimulated with high glucose (HG) was used for parallel validation. The metabolic status of the mice was assessed by regular monitoring of body weight and fasting blood glucose levels. Pathological damage to the sciatic nerve was detected via HE staining. Pain sensitivity was comprehensively evaluated using von Frey tests and hot plate experiments. Western blot, immunofluorescence, ELISA, and RT‒qPCR analyses were used to detect protein and gene expression.
resultsIRF2 was highly expressed in DNP mice and HG-stimulated RAW264.7 macrophages. Knockdown of IRF2 improved pain sensitivity in DNP mice (increased tactile response thresholds and decreased thermal response latency) and ameliorated sciatic nerve injury. Additionally, IRF2 knockdown suppressed M1 macrophage polarization (reduced expression of iNOS, CD80, and CD86) and inflammatory responses (lowered IL-1β, IL-6, and TNF-α levels). Further, IRF2 promoted p-STAT3/STAT3 expression, and treatment with colivelin, a STAT3 activator, attenuated the inhibitory effect of IRF2 knockdown on M1 polarization. Moreover, IRF2 was demonstrated to bind to the IL-6 promoter and increase its transcriptional activity.
conclusionsIRF2 exacerbates DNP by activating IL-6/STAT3 to promote HG-induced M1 macrophage polarization.
Indexed as
Identifiers
42645705What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.